Why Partner | 7th Dermatology Drug Development Summit Europe

Connect With a Global Community of 60+ Dermatology Experts

Dermatology clinical development is entering a more executionally complex and evidence driven phase. High placebo response, subjective endpoints, compressed timelines, and reduced internal capability are forcing biopharma to rely more heavily on specialist partners across clinical delivery, imaging, biomarkers, and formulation. The challenge is no longer access to vendors, but identifying partners with true dermatology literacy who can materially de risk programmes and influence regulatory outcomes.

This meeting has been built around those pressure points. Across CROs, imaging providers, CDMOs, and biomarker specialists, the agenda surfaces where service providers are falling short, where best in class partners are stepping up, and where collaboration models must evolve. For solution providers, this creates clear, differentiated opportunities to position capability against urgent unmet sponsor needs.

Download Brochure

onsite image 7th Dermatology Drug Development Summit EU

What to Expect?

Connect with Active Dermatology Programme Leaders

Build relationships with senior pharma and biotech decision-makers who are actively planning or executing dermatology programmes and seeking partners to address feasibility, recruitment, formulation, biomarker and late-stage clinical challenges.

Position Your Brand at the Centre of Strategic Partnering

Gain high-visibility exposure to C-suite, clinical and regulatory leaders through curated branding across the summit website, agenda, and on-site touchpoints within a focused, senior audience.

Demonstrate Relevant, In-Context Expertise

Showcase your capabilities through speaking opportunities, panel participation, workshops or targeted exhibition placements, positioning your solutions directly within discussions on real dermatology development barriers, rather than generic service pitches.

Access Real-World Market Intelligence

Hear unfiltered insights from dermatology leaders sharing current trial failures, regulatory shifts, access constraints and pipeline strategies, equipping you with actionable intelligence to refine offerings and strengthen competitive positioning.

Key Interest Areas

Our attendees from Glenmark Pharmaceuticals, Noa Therapeutics, Nektar Therapeutics, Sanofi and more are looking for service and solution providers with capabilities in the below areas but not limited to:

Biomarkers and Metabolic Readouts

Regulators are increasingly demanding proof of biological effect, disease modification, and immune normalisation in dermatology programmes. Leading sponsors emphasise the need for biomarker strategies that support mechanism validation, patient stratification, and go no go decision making.

However, sponsors express dissatisfaction with offerings that prioritise scientific novelty without directly answering regulatory relevant questions. Biomarker partners who can link assays and platforms to approval critical endpoints, responder identification, and durable efficacy claims represent a clear unmet need.

Imaging

Dermatology programmes are increasingly constrained by the limitations of visual scoring systems and inter observer variability. Clinical experts repeatedly highlight the need for reproducible, objective assessment, particularly in indications with subjective endpoints and high placebo response.

Despite this, imaging is still treated as exploratory or optional. Imaging companies who can clearly articulate where their technologies replace, strengthen, or de risk primary and secondary endpoints are gaining traction. The commercial opportunity sits with providers who can link imaging directly to statistical power, regulatory confidence, and label relevant claims.

Clinical CROs

Large pharma and emerging biopharma continue to reduce internal clinical operations depth in dermatology, retaining strategy in house while outsourcing execution to CRO partners. However, clinical leaders consistently flag frustration when CROs lack deep indication and endpoint literacy, particularly in diseases with subjective readouts and high placebo response.

There is a clear opportunity for CROs who can demonstrate proactive trial design input, placebo mitigation strategies, endpoint optimisation, and real world regulatory experience in dermatology. Sponsors are actively seeking partners who behave as extension teams rather than execution vendors.

CDMO and Formulation

As dermatology assets move rapidly from Phase 1 into later stage development, sponsors are under pressure to maintain CMC continuity while scaling formulation and manufacturing. Internal formulation and manufacturing capabilities have been reduced or removed entirely across many organisations.

Biopharma leaders cite ongoing frustration with limited dermatology specific expertise and misalignment between clinical, regulatory, and manufacturing timelines. CDMOs with proven topical, biologic, and device combination experience in dermatology are well positioned to differentiate by supporting speed without compromising quality or regulatory readiness.

Hear What Our Past Sponsors Have to Say

Great presentations, excellent roundtable discussions, and enjoyable panel discussions. Really great, focused conference!

David Bruce, Business Development Consultant, Symbio

You had all the right people in attendance.

Richard Panico, Chief Executive Officer, Precefi

It's a focused meeting. It's short and to the point. The speed networking the first morning really breaks the ice.

Colin Davies, Business Development Manager, Contract Pharmaceuticals Limited

Download Brochure

Attending Companies Include

Merck image 7th Dermatology Drug Development Summit EU

Available Inventory

We have a range of inventory from standard booth and speaking slots to more bespoke deliverables such as lanyards, exclusive dinners and tours to help elevate your brand.

Presenting Slots

Leading Innovation

Full Delegate List

Exhibiting

Networking

Bespoke Hosting

Champion the Industry

Branding

Get Involved

This event brings together dermatology focused biopharma leaders and the service providers they rely on most. There are multiple sponsorship and partnership opportunities designed to align your capabilities with clearly defined sponsor pain points.

Download the agenda to see where your expertise fits, or email jake.bennett@hansonwade.com to discuss how to position your organisation within the programme.

Jake Bennet Image 7th Dermatology Drug Development Summit EU

Jake Bennett

Partnerships Director

Stay Front-of-Mind in Dermatology Drug Development

Position your brand at the centre of late-stage dermatology R&D discussions where pharma and biotech leaders are actively evaluating partners.

View Confirmed Sponsors

Connect with Buyers, Not Browsers

Meet senior clinical and development decision-makers in a focused, invitation-only environment designed for real partnership conversations.

Download Event Brochure

Activate Your Value Proposition

Showcase your capabilities through tailored sponsorship, speaking and branding opportunities aligned to active dermatology pipeline needs.

Why Sponsor